What Catalin K 0.005% Treats: Main Uses and Benefits

Catalin K 0.005% (Pirenoxine) is an ophthalmic solution used in the conservative management of chronic eye conditions, focusing on the crystalline lens. Its primary use is centered on addressing the specific symptoms and physical manifestations of cataract formation. This medicine may be relevant for supporting the management of early senile cataract progression.

The medication is commonly applied to manage conditions associated with senile and presenile cataract in their early stages, which include early lens clouding and the resulting blurry vision. This use is relevant in scenarios where surgical intervention is not yet warranted or is being delayed.

“The medicine is relevant for easing symptoms related to progressive loss of lens clarity, and may contribute to improving day-to-day comfort.”

Catalin K may assist with a specific, long-term therapeutic benefit by working to help moderate the rate of cataract progression. This approach helps ease the overall burden of steadily worsening visual symptoms and may contribute to prolonging the period of functional vision during the chronic phase of the condition.

---

Quick Fact: Support for Progressive Visual Deterioration

Regulatory References

1. Kusuri-no-Shiori (Drug Information Sheet) for Catalin K

Eligibility Map: Who can and cannot use Catalin K 0.005% — Official Regulatory Information

Eligibility Scope

Classification	Status	Target Population/Condition
Populations for whom use is allowed	Established	Adult and older adult populations with early-stage senile cataract (age-related).
Populations for whom use is contraindicated	Absolute Prohibition	Patients with a known history of hypersensitivity or allergy to Pirenoxine or any component of the solution.
Populations for whom use is not recommended	Not Established	Pediatric population (children and adolescents).
Conditional Use Status	Benefit-Risk Assessment	Pregnant women or women who may be pregnant; breastfeeding women.

---

Eligibility-Related Restrictions

• Age-related eligibility rules: Use is established in adults and older adults. Use is generally not established and not recommended for children and adolescents, as the condition is age-related.
• Condition-specific eligibility rules: No specific, labeled restrictions related to systemic organ impairment, such as hepatic (liver) or renal (kidney) dysfunction, are documented in official prescribing information for this topical drug.
• Physiological status restrictions: Use in pregnant women is conditional, advised only if the therapeutic benefit outweighs the potential risk. Breastfeeding women should use the medicine with caution.
• Required restriction for contact lenses: Patients who wear soft contact lenses must remove them prior to application and observe a mandatory waiting period before reinserting them.

---

Connection to the Overall Eligibility Profile

Regulatory documents define who can and cannot use this medicine by establishing an absolute prohibition based on confirmed hypersensitivity to the components. The use is primarily directed at adults and older adults. Use in children is not established, and use during pregnancy or lactation is categorized as conditional, requiring a careful assessment as per the official prescribing information.

The official interaction profile for Catalin K 0.005% (Pirenoxine) is highly localized and centers on administration-timing rules rather than systemic drug-drug interactions. The regulatory documentation does not list any systemic medicinal products, food, or supplements that are contraindicated or require dosage adjustment due to metabolic, pharmacokinetic, or pharmacodynamic interaction mechanisms.

Interaction Entity Map (High-Level)	Official Regulatory Status
Systemic Pharmacokinetic Interactions	Not documented.
Contraindicated Combinations	Not documented.
Food, Alcohol, Herbal Product Interactions	Not documented (Specific).

Resulting Interaction Structure

The primary interaction constraints are procedural, establishing rules for co-administration of topical agents.

• Timing Separation for Ophthalmic Solutions: When co-administered with other eye drops, a mandatory separation rule requires that the application of any other ophthalmic solution must be separated by an interval of more than 5 minutes. This rule addresses the localized potential for washout, which could diminish the medicinal effect of either product.
• Restriction with Soft Contact Lenses: The medicine is subject to a restriction requiring the removal of soft contact lenses before administration. Lenses can be reinserted only after a mandated waiting period of 5 to 10 minutes. This restriction is documented to prevent potential interaction with lens material.

Competitive Inhibition of Protein Aggregation

The primary mechanism of Pirenoxine is to competitively inhibit the binding of reactive quinoid substances to the essential sulfhydryl ( -SH) groups on the crystallin proteins in the lens. By blocking this molecular interaction, the drug prevents the irreversible cross-linking and aggregation of the proteins. This action stabilizes the crystallin structure, which is the necessary physiological step to mitigate light scattering and maintain the light transmission capacity of the lens structure.

Modulation of Ocular Oxidative Stress and Metal Chelation

Pirenoxine influences the lens environment through its function as a chelator and antioxidant. It actively scavenges Reactive Oxygen Species (ROS) and sequesters pro-oxidant metal ions (such as Ca^2+ and Fe^3+), neutralizing their ability to catalyze damaging oxidation reactions and protein degradation. This mechanism contributes to the regulation of redox potential and limits the destructive downstream effects of generalized oxidative damage on lens components.

Mechanism Constraints: Stage and Type Dependence

This protective mechanism is inherently stage-dependent and is primarily relevant for processes involving new damage and early aggregation. The stabilizing action is functionally constrained and its relevance is attenuated once massive, irreversible protein aggregates have formed in advanced-stage opacification.

Administration Protocol for Catalin K 0.005%

Catalin K 0.005% (Pirenoxine) is administered via the Topical Ophthalmic route, meaning the solution is applied directly onto the eye's surface. The official instructions delineate specific rules for preparation, dosing, frequency, and duration that structure its use in clinical practice.

---

Dosing and Frequency Schedule

Feature	Official Administration Guideline
Route of Administration	Topical Ophthalmic
Dosing Schedule	Apply 1 to 2 drops at a time
Dosing Frequency	Administer 3 to 5 times a day

---

Procedural Use Requirements

For the two-component form, the solid granules must be dissolved in the solvent just before the first use to achieve the 0.005% concentration. Before administration, hands should be washed, and if the solution has been stored in a cold place, it should be warmed by hand before application. To maintain sterility and ensure proper dosage, the dropper tip must not touch the eye, eyelid, or surrounding skin during application.

Special Conditions and Duration

Administration is generally designated as a continuous, long-term protocol. Patients are instructed not to stop using the medicine unless directed to do so by a healthcare professional. If another ophthalmic drug must be applied concurrently, a waiting period of more than 5 minutes is required between applications. If a dose is missed, it should be applied as soon as possible, but users must never apply two doses at one time to make up for the missed application.

Catalin K 0.005%: Recent Clinical Evidence

Evidence for Use in Early Senile and Presenile Cataract

Research for Catalin K 0.005% has been primarily conducted in the clinical context of early-stage, age-related lens clouding. The evidence landscape includes controlled clinical trials (CCTs), some of which were randomized, that compared the ophthalmic solution against a control group. Studies monitored how symptoms evolved in the observed populations. Additionally, the evidence base draws from long-term observational studies and extensive preclinical research that investigated physiological changes in the eye relevant to the condition.

In these studies, researchers monitored patients to see how their conditions evolved. Outcomes related to physical changes in the lens, such as the progression of opacification, were studied using objective measures like specialized optical equipment. Studies also reported on patterns observed in visual function measures, including changes in visual acuity, during the observation period.

Duration of Studies and Uncertainty

The evidence gathered covers varying periods of time, with controlled trials generally reporting observation periods of approximately 6 months. Certain clinical reports describe follow-up periods extending up to two years (24 months). The consistency of the evidence regarding long-term results is generally characterized as limited in scientific reviews. The available evidence is limited by a restricted number of large-scale, long-duration, double-blind randomized controlled trials (RCTs). Because follow-up durations were limited in key studies, long-term functional measures regarding the visual data observed in studies or the definitive course of disease progression beyond two years are not fully characterized. Research indicates that results apply only to the populations studied, and data for certain groups, such as those with significant comorbidities, remain insufficient.

Key Studies & References

1. Kusuri-no-Shiori (Drug Information Sheet) for Catalin K Eye Drops
2. Pirenoxine as an anti-cataract agent: a review
3. A review of controlled clinical trials of pirenoxine in cataract

Common questions about Catalin K 0.005% (FAQ)

---

Q: What are the main ingredients in Catalin K 0.005% besides the active one?

Official product information confirms that Pirenoxine is the single active substance in this eye drop solution. The formulation also includes non-active ingredients (excipients), such as preservatives and components that help maintain the solution's stability and pH. These specific components are detailed in the full product monograph.

---

Q: Is Catalin K 0.005% meant to cure the underlying condition or just manage symptoms?

According to the official documentation, the primary purpose is the conservative management of early senile cataract. The medicine is intended to help control the progression of the condition by supporting lens transparency, rather than providing a cure for the underlying changes.

---

Q: Is the treatment with Catalin K 0.005% permanent or does the condition return if stopped?

The drug is described in official documents as being generally administered in a long-term manner. Patients are instructed not to stop using the medicine unless directed to do so by a healthcare professional, indicating that ongoing use is considered necessary to manage the condition's progression.

---

Q: Can Catalin K 0.005% be used by someone with known kidney or liver issues?

Regulatory summaries for this topical ophthalmic solution do not list specific safety modifications or dose adjustments for individuals with renal (kidney) or hepatic (liver) impairment. This is consistent with the drug's classification as a topical agent.

---

Q: Are there specific storage instructions for opened vs. unopened components of Catalin K 0.005%?

Official documentation specifies distinct storage conditions based on the medicine's state. The unmixed components should be stored at room temperature (up to 30 C), protected from direct sunlight. Once the components are dissolved to create the reconstituted solution, it must be stored in a cold place (1 C to 15 C) and used within 3 weeks.

---

Q: Is it normal to feel a stinging sensation after applying Catalin K 0.005%?

Stinging eyes are listed in official safety documents as one of the possible adverse reactions reported with the use of this medicine. Localized reactions like this are formally documented as effects that may occur.

---

Q: Can Catalin K 0.005% cause problems with blurry vision?

Blurred vision is listed in regulatory documents as a possible adverse reaction that has been reported with this medicine. As with any ophthalmic solution that lists blurry vision as a reaction, visual function may be temporarily affected.

---

Q: Does Catalin K 0.005% interact with common over-the-counter pain relievers?

The regulatory interaction profile does not list any systemic interactions with other medicines, including common over-the-counter pain relievers. This is consistent with the medicine's topical administration route.

---

Q: Are there any specific vitamins or supplements that interact with Catalin K 0.005%?

Official regulatory documentation does not list any systemic interactions with supplements or vitamins. The interaction profile confirms that the topical agent has no documented systemic interactions with supplements.

---

Q: Is a person with diabetes still eligible to use Catalin K 0.005%?

The fact that the product is indicated in some regulatory documents for use in conditions including mild diabetic cataract indicates the eligibility of patients with diabetes. Official contraindications are limited to known hypersensitivity to the drug’s components.

---

Q: Does Catalin K 0.005% affect the ability to drive or operate machinery?

Since blurred vision is a reported side effect of this medicine, if it occurs, regulatory guidance typically states that activities requiring clear vision, such as driving or operating machinery, may need to be avoided until vision is clear.

---

Q: Do food or drink restrictions apply while using Catalin K 0.005%?

Regulatory documentation confirms that no systemic interactions with food or alcohol are listed for this medicine. This is consistent with the medicine's topical administration route.

---

Q: What should be done if too much Catalin K 0.005% is accidentally applied or swallowed?

Official documentation states that if a person accidentally uses more than the prescribed dose, including accidental ingestion of the topical solution, consultation with a doctor or pharmacist is necessary for guidance.

---

Q: What are the official contraindications listed for Catalin K 0.005%?

According to the official prescribing information, the medicine is strictly contraindicated (prohibited) in any individual with a known history of hypersensitivity or allergic reaction to Pirenoxine or any other component used in the ophthalmic solution formulation.

---

Q: Are there reports of allergic reactions to Catalin K 0.005%?

Official safety information notes that known allergic reactions, such as itchiness or contact dermatitis of the eyelid, are reported adverse effects. Official safety information requires that a patient consult a healthcare professional if signs of an allergic reaction, such as itching or rash, are observed.

---

Q: Why is Catalin K 0.005% only available as a liquid or solution?

The medicine is formulated as a sterile, aqueous ophthalmic solution because this route of administration is necessary to ensure direct application to the eye's surface. This localized delivery supports the active ingredient's action on the lens proteins.

---

Q: How is the action of Catalin K 0.005% different from a simple lubricating eye drop?

Catalin K 0.005% is classified as an anti-cataract agent. Its mechanism involves inhibiting protein aggregation and reducing oxidative stress within the lens, which is a therapeutic action distinct from simple lubricating eye drops that primarily address surface dryness.

How to Store and Dispose of Catalin K 0.005%

The official storage conditions for Catalin K 0.005% ophthalmic solution distinguish between the unmixed components and the reconstituted solution.

---

Storage Requirements

Product State	Temperature Requirement	Protection Requirement
Unmixed Components	Room temperature (1 C to 30 C)	Away from direct sunlight
Reconstituted Solution	Cold place (1 C to 15 C)	Away from light

The reconstituted solution has an official post-dissolution stability limit and must be used within 3 weeks. To maintain the medicine's integrity, it must not be transferred to any other container and must be kept out of the reach of children. After 3 weeks, any remainder must be discarded, and users should consult a pharmacy or medical institution for guidance on proper disposal.